Patritumab deruxtecan starts phase 3 Daiichi Sankyo meanwhile has started a phase 3 trial of another ADC – patritumab deruxtecan – comparing the drug to chemotherapy as a second-line therapy ...

Patritumab deruxtecan, which is currently leading the anti-HER3 pipeline, has shown efficacy in heavily pre-treated patients with EGFR-mutated NSCLC previously treated with multiple EGFR ...

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals ...

Dr. Gandara has served on the Board of Directors or held other leadership positions with Response Genetics, Inc.; has received research funding from Abbott Laboratories, Bristol-Myers Squibb ...

New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved AstraZeneca's protocol amendment proposal to study anticancer drug ...

It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for ...